The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

March 25, 2025 • In a new book, author John Green traces how the disease has impacted culture, geography, and even fashion over the centuries. Tuberculosis (TB) has had an incredibly large ...